U.S. markets closed
  • S&P Futures

    3,604.50
    +3.00 (+0.08%)
     
  • Dow Futures

    28,866.00
    +65.00 (+0.23%)
     
  • Nasdaq Futures

    11,015.75
    -19.75 (-0.18%)
     
  • Russell 2000 Futures

    1,673.10
    +3.30 (+0.20%)
     
  • Crude Oil

    81.98
    +2.49 (+3.13%)
     
  • Gold

    1,672.00
    0.00 (0.00%)
     
  • Silver

    19.10
    +0.07 (+0.35%)
     
  • EUR/USD

    0.9802
    +0.0001 (+0.01%)
     
  • 10-Yr Bond

    3.8040
    +0.0570 (+1.52%)
     
  • Vix

    31.62
    -0.22 (-0.69%)
     
  • GBP/USD

    1.1141
    -0.0025 (-0.22%)
     
  • USD/JPY

    144.8000
    +0.0710 (+0.05%)
     
  • BTC-USD

    19,034.50
    -292.01 (-1.51%)
     
  • CMC Crypto 200

    443.49
    +0.06 (+0.01%)
     
  • FTSE 100

    6,893.81
    +12.22 (+0.18%)
     
  • Nikkei 225

    25,937.21
    -484.89 (-1.84%)
     

We Like These Underlying Return On Capital Trends At Amedisys (NASDAQ:AMED)

·2 min read

Did you know there are some financial metrics that can provide clues of a potential multi-bagger? In a perfect world, we'd like to see a company investing more capital into its business and ideally the returns earned from that capital are also increasing. If you see this, it typically means it's a company with a great business model and plenty of profitable reinvestment opportunities. With that in mind, we've noticed some promising trends at Amedisys (NASDAQ:AMED) so let's look a bit deeper.

Return On Capital Employed (ROCE): What is it?

For those who don't know, ROCE is a measure of a company's yearly pre-tax profit (its return), relative to the capital employed in the business. Analysts use this formula to calculate it for Amedisys:

Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities)

0.18 = US$268m ÷ (US$1.9b - US$374m) (Based on the trailing twelve months to December 2021).

So, Amedisys has an ROCE of 18%. In absolute terms, that's a satisfactory return, but compared to the Healthcare industry average of 11% it's much better.

View our latest analysis for Amedisys

roce
roce

In the above chart we have measured Amedisys' prior ROCE against its prior performance, but the future is arguably more important. If you're interested, you can view the analysts predictions in our free report on analyst forecasts for the company.

What The Trend Of ROCE Can Tell Us

We like the trends that we're seeing from Amedisys. The numbers show that in the last five years, the returns generated on capital employed have grown considerably to 18%. The company is effectively making more money per dollar of capital used, and it's worth noting that the amount of capital has increased too, by 168%. So we're very much inspired by what we're seeing at Amedisys thanks to its ability to profitably reinvest capital.

The Bottom Line On Amedisys' ROCE

A company that is growing its returns on capital and can consistently reinvest in itself is a highly sought after trait, and that's what Amedisys has. And a remarkable 215% total return over the last five years tells us that investors are expecting more good things to come in the future. Therefore, we think it would be worth your time to check if these trends are going to continue.

One more thing to note, we've identified 1 warning sign with Amedisys and understanding it should be part of your investment process.

For those who like to invest in solid companies, check out this free list of companies with solid balance sheets and high returns on equity.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.